科学图书馆
-
From ACE Inhibitors/ARBs to ARNIs in Coronary Artery Disease and Heart Failure (Part 2/5)DP Leong, JJV McMurray, PG Joseph et al. -
The Management of Atrial Fibrillation in Heart Failure: An Expert Panel ConsensusD Farmakis, C Chrysohoou, G Giamouzis et al.
-
The prevalence and importance of frailty in heart failure with reduced ejection fraction - an analysis of PARADIGM-HF and ATMOSPHEREDewan P, Jackson A, Jhund PS et al.
-
Modifiable lifestyle factors and heart failure: A Mendelian randomization studyS van Oort, JWJ Beulens, AJ van Ballegooijen et al.
-
Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to Age: Insights From DAPA-HFMartinez FA, Serenelli M, Nicolau JC et al.
-
Empagliflozin Increases Cardiac Energy Production in Diabetes - Novel Translational Insights Into the Heart Failure Benefits of SGLT2 InhibitorsS Verma, S Rawat, KL Ho et al.
-
Angiotensin–Neprilysin Inhibition in Heart Failure with Preserved Ejection FractionSD Solomon, the PARAGON-HF Investigators and Committees. JohnJV McMurray,
-
A trial to evaluate the effect of the sodium-glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF)McMurray JJV, DeMets DL, DAPA-HF Committees and Investigators.
http://www.cbsmd.cn Contact us by cbs@cbsmd.cn
Copyright ⓒ CBSMD Nanjing China. All rights reserved.
